Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease

NMA HREC Reference Number: HREC/17/MHS/15
NMA SSA Reference Number: SSA/17/MonH/451
Monash Health Ref: RES-17-0000-517X